Our Mission

Our Mission

AllerGenis' mission is to develop precision diagnostic solutions that can help healthcare providers better assess and manage the well-being of millions of food allergy patients. Specializing in immunology and bioinformatics, we created a highly multiplexed analytical platform to address the limitations of current food allergy diagnostic tests.

Our story

Our story

AllerGenis develops precision, data driven diagnostics to help healthcare providers more accurately and safely diagnose, assess, and monitor patients with food allergies. The company was founded out of a collaboration with Hugh Sampson MD, of the Icahn School of Medicine at Mount Sinai. AllerGenis’ technology platform is based on immunological research by Dr. Sampson, and leverages AllerGenis’ expertise in improving sensitivity of diagnostic tests. Mount Sinai Health System licensed its proprietary epitope mapping platform to AllerGenis, which the company is using to create the largest food allergy knowledge base populated by individual patient epitope signatures derived from epitope mapping, clinical history, and patient-reported outcomes to gain clinical insights. 

Our Team

Meet the AllerGenis leadership team.

Executive Leadership

Jim Garner

Jim Garner

CEO and Board Member

Jim has over 30 years of experience providing products and services to help families and doctors better diagnose and manage health conditions.

Jim was the Chief Business Officer of Integrated Diagnostics, a diagnostics company developing technology for early detection, prediction and prevention of disease. Prior to that he was Senior Vice President of Global Sales and Senior Director of Corporate Development for UnitedHealth Group, Director of Marketing & Corporate Development at Elan Diagnostics and Sales Manager at DIANON Systems.

Jim received the Meritorious Service Medal among other honors while serving as Captain in the United States Army where he was Air-Cavalry Troop Commander, Aviation Task Force Operations Officer, and Helicopter Attack Pilot, among other roles and distinctions.

Jim lives in Florida with his family where he enjoys surfing, golfing and tennis with his wife and two sons.

Russ Fein

Russ Fein

CFO and Board Member

Russ Fein began his career in 1987 in the Mergers and Acquisitions department of Jefferies & Company, Inc. where he worked on numerous complex transactions. He then spent a number of years in the merchant banking field where he negotiated acquisitions and investments both as principal and agent and often stepped in as COO and/or CFO of portfolio companies, leading growth strategies and building professional organizations around entrepreneurial businesses.

In 1995, he left the investment banking field to work full time in senior management roles at a number of small and large operating businesses, including a chain of martial art studios, an Internet incubator and most recently as the Vice President, Worldwide Business Operations for Westcon Group, a $4 billion distributor of communications and technology equipment, where he also held the role of General Manager for a $300mm U.S. division.

Russ received his MBA from the University of Chicago Graduate School of Business and graduated from Union College with honors in Managerial Economics.

Thomas

Thomas L. Vollmers

Head of Strategic Partnerships & Commercial Strategy

Thomas is an accomplished Sales and Marketing Leader in the Pharmaceutical and Biotechnology Industry with domain expertise in Precision Medicine and Companion Diagnostics. Through positions at Pfizer, ViiV Healthcare, GSK and AstraZeneca, Thomas gained extensive US & Global companion diagnostic commercial launch experience in the therapeutic areas of HIV and Oncology.

Robert

Robert C. Getts

PhD, Chief Science Officer

Dr. Getts has over 25 years of biotech research and development experience. The majority of this experience has been focused on the development of biological assays, and reagents to improve life science and diagnostic detection of disease markers as well as improve the delivery of therapeutic molecules. Bob has:

  • Over 35 peer-review publications, abstracts, and presentations
  • More than 20 issued patents and more than 35 submitted patent applications under review
Paul Kearney

Paul Kearney

Head of Product & Clinical Development

Paul is an accomplished scientific leader having invented, developed and commercialized several diagnostic tests. Most recently he has advised Sera Prognostics on the development and launch of their PreTRM product. Paul oversees the evidence development strategy for Sera Prognostics.

Board of Directors

Vijay Aggarwal

Vijay Aggarwal

PhD, Chairman

Vijay has over thirty years of experience in both pharmaceutical services and clinical diagnostics. He is currently a Partner of The Channel Group, LLC and its affiliate, BioMed Transition Partners, a New York-based life sciences venture development and management firm, engaging in venture formation and transactions.

Most recently, Dr. Aggarwal was President and CEO of Aureon Laboratories, Inc., a predictive pathology company offering advanced tissue analysis services to practicing physicians and the pharmaceutical industry. Previously, Dr. Aggarwal was President of Quest Diagnostic Ventures, where he had responsibility for new technology, new business models, clinical trials testing, and direct-to-consumer strategies.

Earlier in his career, Dr. Aggarwal held many positions with SmithKline Beecham Clinical Laboratories, including direct responsibility for all of SBCL’s U.S.-based laboratories as Executive Vice President of Laboratories, Vice President of Managed Care. He earned a BA in Chemistry from Case Western Reserve University and a Ph.D. in Pharmacology/Toxicology from the Medical College of Virginia.

Hugh A

Hugh A. Sampson

M.D, Board Member

Dr. Sampson is the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai. He is the Emeritus Director of the Jaffe Food Allergy Institute and the Director and PI of the NIH-sponsored CTSA program, Conduits –the Institutes for Translational Sciences at Icahn School of Medicine at Mount Sinai.

Dr. Sampson's research interests have focused on food allergic disorders, and now include work on the pathogenesis of food-induced anaphylaxis, characterization of allergenic food proteins and their processing by the immune system, genetics of food allergy, development of novel diagnostic tests, and mechanisms of immunotherapeutic strategies for treating food allergies including basic studies and clinical trials in oral, sublingual and epicutaneous immunotherapy and the potential use of biologics, such as anti-IgE and anti-cytokine monoclonal antibodies. His research is funded by a number of grants from the National Institutes of Health and private foundations (Food Allergy Research and Education), and he is the PI on the NIH-sponsored Consortium of Food Allergy Research.

David A

David A. Esposito

Board Member

David Esposito is President and CEO of ONL Therapeutics, a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions.​ As an experienced healthcare executive, David has built and scaled multiple companies that resulted in successful exits to strategic buyers.

David is the former CEO of Armune BioScience where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. The Company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017.

He was President of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) for in 2011. David began his career as a sales representative with Merck & Co. Inc. and rose through the ranks of sales, marketing and commercial strategy for the US Division.

David is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.

Kimberly L

Kimberly L. Sablich

Board Member

Kim is Executive Vice President, General Manager of North America at Jazz Pharmaceuticals where she leads the North American regional business structure, which brings together Medical Affairs, Commercial, and Market Access teams to create a strategically-aligned and integrated customer-facing organization. Overall, Kim has 23 years of commercial experience in the biopharmaceutical industry having spent the majority of her career in Marketing at Merck and Glaxo SmithKline (GSK).

She was previously Chief Commercial Officer at Myovant Sciences. Prior to Myovant Sciences, Kim was Vice President of Primary Care Marketing in the U.S. for GSK and was responsible for revenue forecasts, strategies, and execution plans for a broad portfolio of respiratory products accounting for over $4B in annual net sales, including ADVAIR, BREO, ANORO, INCRUSE, and TRELEGY. She earlier worked for GSK in the US as Vice President of Global Medicine Commercialization for a pipeline of cardiovascular and renal anemia assets and in the US as Vice President, Vaccines Commercial Strategies.

Kim started her career at Merck where she held many positions in the commercial organization with a heavy focus on both physician and consumer marketing in the cardiovascular, respiratory, and vaccines business areas. During this time she played key roles in the successful launches of Cozaar, Singulair, and Gardasil. Kim earned her B.S. degree from Denison University and her M.B.A. from The Wharton School of the University of Pennsylvania.

John C

John C. Simons

Board Member

John Simons has spent 33 years as a banker and advisor to small and mid-size businesses and the families that own them. John was formerly an Executive Vice President for Bank of America (formerly Fleet National Bank) in the Regional Commercial Services Group, responsible for small business, middle market and corporate banking in New York City, Long Island, New Jersey and the Hudson Valley area. He was also Market Executive for FleetBoston Financial’s activities in New York City. Prior to joining Fleet, John was a Senior Vice President with Chase Manhattan Bank. He began his career with Chemical Bank in 1983.

John is a Director of The United Hospital Fund, a Trustee of amfAR, The American Foundation for Aids Research, and a former Trustee of the Brooklyn Academy of Music. John was also Chairman of the Lincoln Center Business Council and a member of Lincoln Center Corporate Fund. John was appointed by Mayor Bloomberg in 2003 to be a member of the Mayor’s Fund to Advance New York City. John has a bachelor’s degree from Trinity College.

senior staff

Benjamin Gerson

M.D, Laboratory Director

A graduate of the Jefferson Medical College Dr. Gerson is Certified in Anatomic & Clinical Pathology and in Toxicology, having trained at the Johns Hopkins Hospital and Johns Hopkins University School of Medicine. Additionally he is certified as a Medical Review Officer (MRO) by MROCC. His academic career started on the faculty of the Harvard Medical School. Presently he is with the Department of Pathology and Cellular Biology - Jefferson Medical College. Among his relevant activities, Dr. Gerson is an officer of the Board of Directors of MROCC; he is a member of and an Officer of the National Sleep Foundation (NSF); a member of the Board of Directors of the Pennsylvania Occupational and Environmental Medicine Society (POEMS), has been Professor of Pathology and of Pharmacology and also Clinical Professor of Occupational Medicine, Director - Laboratory of Analytical Toxicology all at Boston University School of Medicine; and has been a member of the Board of Directors of the Substance Abuse Professional Administrators Association (SAPAA). Other Significant past activities include having been Chairman of the Clinical Devices Panel for the FDA. Dr. Gerson has served on Boards of Directors and/or Scientific Advisory Boards of various companies.

Robert Reinhardt

M.D, Clinical Advisor

As a medical and clinical consultant to AllerGenis, Rob brings extensive experience and expertise gained from two parallel career tracks: the medical diagnostics industry and academic family medicine. As CMO at PhadiaUS, he was an integral part of the leadership team which transformed ImmunoCAP, from an esoteric diagnostic test ordered only by allergy specialists to a simple everyday blood test used also by primary care.

William J. Pignato

Regulatory Affairs

Bill Pignato is the Founder and Principal of W.J. Pignato & Associates, LLC a Boston based consulting firm specializing in global regulatory affairs strategy, which is focused on in vitro diagnostics, medical devices, companion diagnostics and precision medicine, drug/diagnostics co-development and the regulatory deployment of new technologies. Previously, Bill was the Vice President, Global Head of Regulatory Affairs, Companion Diagnostics at Novartis where he led the companion diagnostic regulatory program in support of the company’s novel therapeutics in oncology and general medicine. He previously worked at Genentech, Inc leading the regulatory effort specific to the company’s companion diagnostic initiatives. Bill brings 35 years of strategic global diagnostic regulatory affairs experience in support of bringing products to market, including working on more than 60 drug/companion diagnostic co-development programs. Prior positions include Vice President of Regulatory Affairs for EXACT Sciences Corp., an applied genomics company focused on the early detection of colorectal cancer and Vice President of Regulatory Affairs for Valeo Medical. He has also previously held senior regulatory positions at Bayer Diagnostics, Chiron Diagnostics and Ciba-Corning Diagnostics. Bill has been active in numerous FDA/Industry cooperative activities regarding regulatory policy impacting diagnostic devices. He has spoken widely on a number of regulatory issues and challenges associated with commercialization of in vitro diagnostic technologies, including personalized medicine, companion diagnostics and drug/diagnostic co-development.

Cindy Yule

Business Analyst

Cindy has over fifteen years of expertise in all areas of business and sales operations including financial modeling, financial planning, sales force design, sales target setting, measurement, forecasting, and sales incentive compensation plan design.